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This study describes variations in tumour growth patterns which occur when
changes in the routes of inoculation and mouse strain are used to introduce tumours
into established murine model systems that are known to vary in location and
aggression. Intraperitoneal, subcutaneous, intravenous and hydrodynamic inocula-
tions of B16F10 cells were compared among CD-1, C57BL/6 and Balb/c mice. Most
surprisingly, allogeneic tumour growth in Balb/c mice after intravenous and hydro-
dynamic inoculation of B16F10 cells was faster than tumour growth in the syngeneic
C57BL/6 mice. These and other variations in the tumour growth patterns described
here can help provide the researcher with more experimental control when planning
to use the optimal tumour model for any particular study.
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Introduction
In vivo testing of cancer treatment is a necessary step in
drug development, and employing an effective and relevant
tumour model is essential for obtaining convincing results
and determining accurate conclusions. For decades, murine
models have been the most facile and efficient of the
tumour models (Leenders et al. 2008). Tumours have been
generated in vivo through carcinogenic (Imaoka et al. 2009;
Ramos et al. 2012) or viral induction (Lewis et al. 2001),
through genetic engineering to increase susceptibility to
spontaneous tumour formation (Heyer et al. 2010; Politi &
Pao 2011), and, most commonly, by inoculating mice with
cancer cells that have been grown in vitro (Tsutsumi et al.
2009; Oliva et al. 2012).
Intraperitoneal (i.p.), subcutaneous (s.c.), intravenous
(i.v.) and hydrodynamic (h.d.) (Liu et al. 1999; Zhang
et al. 1999) injections are all viable routes for inoculation,
and each produces a distinct pattern of tumour growth.
Hydrodynamic injection is carried out by quickly pushing
1.6 ml (equal to the total blood volume of the mouse)
of cells/solution through the tail vein (Liu et al. 1999;
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Zhang et al. 1999). Quickly injecting this large volume
distends and allows efficient delivery to tissues, especially
the liver. Thus, while the site of injection for both i.v.
and h.d. inoculation is the tail vein, the sites of tumour
growth are quite distinct (Kang et al. 2009; Li et al.
2011). In addition, another factor which may affect the
fine tuning of murine tumour model growth patterns are
differences between the susceptibility between growth pat-
terns which can occur between the mouse strains them-
selves. For a given route of inoculation, CD-1, C57BL/6
(C57), and Balb/c mice can generate significant differences
in tumour growth rates and patterns, but there are few
reports where this question specifically has been studied in
detail. This report describes how differences in the strain
or route of B16F10 murine melanoma inoculation can
generate new and distinct tumour models for use in
tumour characterization or therapeutic experiments.
Materials and methods
B16F10 murine melanoma cells were used for this study.
Cells were maintained in DMEM with penicillin/strepto-
mycin and 10% foetal bovine serum. Female CD-1, C57
and Balb/c mice were purchased from the University of
North Carolina’s in-house breeding facility.
CD-1, C57 and Balb/c mice were ordered at the same time
and were all aged 6 weeks at the time of inoculation. Four
different inoculation routes were studied (n = 5 for each
mouse strain and inoculation route, for a total of 12 different
groups). All mice were inoculated on the same day with the
same number, passage and population of cells. For i.v. injec-
tion, all three strains of mice were inoculated with 2 9 105
B16F10 cells in 200 ll PBS through the tail vein. For h.d.
injection, all three strains of mice were inoculated with
2 9 105 B16F10 cells suspended in 1.6 ml of PBS by injecting
the entire volume through the tail vein within a few seconds.
For s.c. injection, all three strains of mice were inoculated
with 2 9 105 B16F10 cells in 100 ll PBS. For i.p. injection,
all three strains of mice were inoculated with 2 9 105
B16F10 cells in 200 ll PBS.
All mice were sacrificed 14 days after inoculation to allow
quantitative comparisons between strains and routes of inoc-
ulation. Organs were fixed in 4% paraformaldehyde, and
relevant organs were embedded in paraffin. These organs
were sectioned and stained with H&E to visualize regions
of tumour growth.
s.c. and i.p. tumour growth was quantified by dissecting
and weighing the tumours. Lung tumour growth was mea-
sured by counting tumour nodules on each lung. Statistical
analysis was performed using Student’s t-test and Holm–
Sidak test to determine the statistical significance.
Ethical approval statement
All work performed on animals was in accordance with and
permitted by the University of North Carolina Institutional
Animal Care and Use Committee, protocol #14-045.
Results and discussion
Tumour growth rates were compared among CD-1, C57
and Balb/c mice 14 days after inoculation with 2 9 105
B16F10 cells. Five mice from each of the three mouse strains
were inoculated via one of four different routes: intravenous
(i.v.), hydrodynamic (h.d.), subcutaneous (s.c.) and intraperi-
toneal (i.p.). When the mice were inoculated i.v., all three
strains of mice developed tumours specifically in their lungs,
and the rates of tumour growth differed depending on
mouse strain. Figure 1 shows that the C57 mice, the syn-
geneic hosts for B16F10 cells, rapidly developed tumours
exclusively in their lungs. This result was expected, as this
strain and cell line has long been used as a melanoma lung
metastasis model (Lin et al. 1998; Peer & Margalit 2004).
Unexpectedly, the tumour growth rate in the lungs of Balb/c
mice after i.v. inoculation was significantly faster than that
in C57 mice. This result was surprising because B16F10
inoculation in Balb/c mice should constitute a less robust
allograft model when compared to the syngraft model in
C57 mice. In contrast, the outbred and more heterozygous
(a)
(b)
Figure 1 Tumour growth after i.v. inoculation in CD-1, C57
and Balb/c mice. Fourteen days after i.v. inoculation of 2 9 105
B16F10 cells in 200 ll PBS, mice were sacrificed and their
organs were fixed in 4% paraformaldehyde. (a) Tumour growth
in lungs. Tumour growth in Balb/c lungs was much faster than
that in C57 or CD-1 lungs. (b) Representative liver, kidney and
spleen from each strain showing lack of tumour growth outside
of the lung.
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CD-1 strain of mice developed lung tumours significantly
more slowly than C57 mice.
Strain- and route-dependent differences in tumour growth
were also observed after h.d. inoculation (Figure 2). The
large injection volume forced the injected tumour cells into
several organs, especially the liver, generating tumours in the
liver, lung, kidney, spleen and peritoneum. An overview of
tumour growth patterns can be found in Table 1. The
(a)
(b) (c) (d)
Figure 2 Tumour growth after h.d. inoculation in CD-1, C57 and Balb/c mice. Fourteen days after inoculation of 2 9 105 B16F10
cells in 1.6 ml PBS, mice were sacrificed and their organs were fixed in 4% paraformaldehyde. (a) Tumour growth in lungs. Tumour
growth in Balb/c lungs was again faster than that in C57 or CD-1 lungs, but lung tumour growth was overall slower than the lung
tumour growth after i.v. inoculation. (b,c,d) Representative liver, kidney, spleen and intestines from C57, Balb/c and CD-1 mice,
respectively, showing broad tumour growth outside of the lung. Again, Balb/c mice showed faster tumour growth in liver than did
C57 or CD-1 mice.
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tumour growth rate in the lungs after h.d. inoculation was
significantly slower than its rate after intravenous inoculation
(Figure 3), most probably because the force of h.d. injection
is sufficient to push the tumour cells through the lung capil-
laries and into downstream organs. Again, tumour growth in
Balb/c mice was faster than that in C57 mice, although
tumours were present in the liver, lung, kidney, spleen and
peritoneum in all five mice per group. The tumour growth
pattern after h.d. inoculation in both C57 and Balb/c mice
was consistent with the literature describing growth in C57
mice (Kang et al. 2009; Li et al. 2011). Tumours in CD-1
mice grew more slowly in the lung, but did not show many
signs of growth in other organs after h.d. inoculation. The
histological findings illustrated in Figure 4 show differences
in lung and liver tumour burden after i.v. and h.d. inocula-
tion respectively.
Other routes of B16F10 inoculation were performed to
investigate any other strain-dependent tumour growth differ-
ences. Intraperitoneal tumour growth after i.p. injection was
very fast in all three mouse strains, filling the peritoneal cav-
ity and surrounding the intestines, spleen and kidneys,
although the take rate in CD-1 mice was only three of the
five inoculated mice. There was no statistical difference
between tumour growth rates among all three strains, and
at the conclusion of the study, no tumours had yet metasta-
sized to the lungs (data not shown). Subcutaneous tumour
growth after s.c. injection was slowest in CD-1 mice and
significantly faster in C57 mice (Figure 5). Subcutaneous
tumours in Balb/c mice grew more slowly than those in C57
mice, but not significantly so.
The differences in tumour growth patterns shown here
provide some interesting, albeit unexpected, results. The syn-
geneic nature of B16F10 inoculation in C57 mice is evi-
denced in its rapid tumour growth along all inoculation
routes, but what is most interesting is the even faster tumour
growth in Balb/c mice after i.v. and h.d. inoculation, even
though the introduction of B16F10 cells generates an allo-
geneic model in which tumour growth should be suppressed
by the host’s immune system. The outbred CD-1 mice did
not show this increased tumour growth; their tumours grow
more slowly than the tumours of both C57 and Balb/c mice.
The differences in the observed rate of tumour growth
among CD-1, C57 and Balb/c mice have generated many
questions. It is simple enough to explain how the syngeneic
C57 host may not mount a robust immune response against
the injected B16F10 cells, resulting in a fast, widespread
tumour growth among several routes of inoculation. Immune
surveillance against B16F10 cells may also play a role in the
slower tumour growth in the outbred CD-1 mice. The most
puzzling is the consistently faster tumour growth in Balb/c
mice after i.v. and h.d. inoculation, both of which use injec-
tion via the tail vein as the route of inoculation. This unex-
pected result may have occurred at least in part because of
inadequate rejection of the allogeneic cells by the Balb/c host.
Table 1 Overview of tumour growth patterns across all tested
strains and routes of inoculation
Mice with tumours present in this organ
Liver Spleen Kidney Lung Peritoneum s.c.
Hydrodynamic
C57BL/6 5/5 5/5 5/5 5/5 4/5 0/5
Balb/c 5/5 5/5 5/5 5/5 5/5 0/5
CD 1 0/5 0/5 1/5 5/5 1/5 0/5
Intravenous
C57BL/6 0/4 0/4 0/4 4/4 0/4 0/4
Balb/c 0/4 0/4 0/4 4/4 0/4 0/4
CD 1 0/4 0/4 0/4 4/4 0/4 0/4
Intraperitoneal
C57BL/6 5/5 5/5 5/5 0/5 5/5 0/5
Balb/c 5/5 5/5 5/5 0/5 5/5 0/5
CD 1 3/5 3/5 3/5 0/5 3/5 0/5
Subcutaneous
C57BL/6 0/5 0/5 0/5 0/5 0/5 5/5
Balb/c 0/5 0/5 0/5 0/5 0/5 5/5
CD 1 0/5 0/5 0/5 0/5 0/5 5/5
Figure 3 (a) Quantification of tumour nodes on lungs after i.v. or h.d. inoculation. Tumour nodes per mouse were counted and
averaged. (b) Relevant P-values were calculated using a Student’s t-test, and statistical significance was confirmed for all comparisons
using the Holm–Sidak corrections. Because the tumour growth in Balb/c mice that received i.v. inoculation covered nearly the entire
lung, tumour nodes were unable to be quantified, but the overall tumour burden in these mice was obviously much higher than in all
other groups. P-values were not calculated for comparisons between Balb/c i.v. and other groups.
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The cells may have overwhelmed the immune system in the
Balb/c mice or induced a immune tolerance providing a niche
for the tumour cells to grow quickly. Recent literature has
shown that B16F10 cells produce anti-inflammatory and
immunosuppressive microvesicles containing phos-
phatidylserine and that these microvesicles contribute to
increased tumour growth in Balb/c mice (Luize et al. 2009).
While Balb/c and C57 mice were both used in this study,
tumour growth in the different strains was not compared
directly. Thus the nature of the immunological differences
between the routes of innoculation, combined with mouse
strain, should be taken into account when mice are used as
animal models in the field of cancer therapy.
Conclusions
The differences in tumour growth among the different strains
and inoculation routes implies that they constitute a series of
independent B16F10 tumour models. Intravenous inocula-
tion into C57 mice generates the expected fast-growing lung
metastasis model, while h.d. inoculation in C57 mice pro-
duces a model in which metastasis has spread throughout the
body. Inoculations in Balb/c mice produce aggressive, allo-
geneic tumour models that might be used to study how
immune contributions affect tumour growth, while the CD-1
models provide less aggressive tumour growth that could be
used to replicate slow-growing tumours. The differences in
Figure 4 H&E-stained sections of lung and liver in CD-1, C57 and Balb/c mice. Tumour burden in Balb/c i.v. lungs is high, and the
normal epithelium is surrounded with blood. No livers show tumour burden after i.v. inoculation, but there is a large burden in C57
and Balb/c tumours after h.d. inoculation.
(a) (b)
Figure 5 Tumour growth after s.c. inoculation in CD-1, C57 and Balb/c mice. Fourteen days after s.c. inoculation of 2 9 105
B16F10 cells in 100 ll PBS, mice were sacrificed, and tumours were harvested and weighed. (a) Relative s.c. tumour sizes in all three
strains; (b) Average tumour weights; **P = 0.01.
International Journal of Experimental Pathology, 2016, 97, 351–356
Novel murine tumour models 355
growth speed will allow researchers to select a more or less
aggressive tumour model that will best fit for their studies.
Identifying the variations in tumour models which could
be generated by modifying mouse strain and route of inocu-
lation might have many practical applications. The models
described here provide some indication of the range of pos-
sible selection, but only compares the growth of one tumour
line in a combination of three mouse strains and four routes
of inoculation. If this effort is expanded to include other
mouse strains and tumour lines, this could generate an
extremely useful source to aid scientists in choosing the
most effective model for their research.
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